Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 103 participants.
Also called NCT05049096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 103 participants
- Registry
-
NCT05049096
-
- Other papers using this trial's data
- Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT05049096. Randomized; triple masking; primary purpose treatment. Start 2021-11-01 (actual); primary completion 2023-11-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension
- Acronym
- PARADISE-HTN
- Condition
- Hypertension
- Condition
- Blood Pressure
- Condition
- Cardiovascular Diseases
- Intervention (Device)
- focused power ultrasound mediate inferior perirenal adipose tussue modification
- Intervention (Device)
- sham-control group
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
Record details
- Record id
cardio:ct-nct05049096- Content hash
d7faeffd1c1ee0a74a779f1156a1c416ed8bdfe07bf0173d2bb2fbeb26501f37